DOSSIER · 13F-HR · Q2 2026

Nan Fung Group Holdings Ltd

$131M in tracked AUM across 25 positions as of Q2 2026.

NF
CIK 0001782539 · last filed Jun 30, 2026
Total AUM
$131M
as of Q2 2026
Holdings
25
—
positions
Whale Score
67
67
tracked
Activity
—
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive SEC 13F Analysis: Nan Fung Group Holdings Ltd
1. Portfolio Overview

Nan Fung Group Holdings Ltd reported a significant contraction in its US equity portfolio for the period ending September 30, 2025. The total portfolio value decreased by 25.9%, dropping from $63.43M to $46.97M. This reduction in assets under management (AUM) was driven primarily by active deleveraging rather than just market depreciation, as the fund executed a major rotation out of existing pos...

The portfolio remains highly concentrated, consisting of only 16 holdings. The turnover rate was exceptionally high this quarter, characterized by a "clean sweep" strategy where the fund exited 8 positions (accounting for approximately $30.9M in value from the previous quarter) and initiated 4 new positions. Despite the high activity, the majority of the portfolio (11 positions) remained unchanged in share count, suggesting a "hold and rotate" approach around a stable core of long-term convictions.

2. Key Holdings
Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
MPLT
MAPLIGHT THERAPEUTICS INC
$35M971K26.5%
02
LBRX
LB PHARMACEUTICALS INC
$20M631K15.6%
03
EVMN
EVOMMUNE INC
$19M1.4M14.6%
04
HELP
CYBIN INC
$7M987K5.0%
05
INCY
INCYTE CORP
$6M54K4.6%
06
RYTM
RHYTHM PHARMACEUTICALS INC
$5M49K4.1%
07
ONC
BEONE MEDICINES LTD
$4M16K3.4%
08
H5870P102
OCULIS HOLDING AG
$4M301K3.2%
09
K08588103
ASCENDIS PHARMA A/S
$4M14K2.8%
10
RVMD
REVOLUTION MEDICINES INC
$4M19K2.7%

Filing history

2026Q2Jun 30
$131M▲ 8.4%
25 positionsView →
2026Q1Mar 31
$121M▲ 8.5%
24 positionsView →
2025Q4Dec 31
$112M▲ 137.9%
27 positionsView →
2025Q3Sep 30
$47M▼ 25.9%
16 positionsLocked
2025Q2Jun 30
$63M▲ 3.6%
20 positionsLocked
2025Q1Mar 31
$61M▼ 47.6%
21 positionsLocked
2024Q4Dec 31
$117M▲ 0.7%
35 positionsLocked
2024Q3Sep 30
$116M▲ 23.8%
38 positionsLocked
2024Q2Jun 30
$94M▼ 13.2%
44 positionsLocked
2024Q1Mar 31
$108M▼ 32.8%
45 positionsLocked
2023Q4Dec 31
$161M▲ 30.0%
39 positionsLocked
2023Q3Sep 30
$123M▼ 21.1%
39 positionsLocked
Showing 12 of 21